82 results match your criteria Vulvar-Vaginal Reconstruction


Incidences and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis.

Gynecol Oncol 2018 09 24;150(3):501-508. Epub 2018 Jul 24.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, NY, USA.

Objective: To examine incidences and risk factors for metachronous vulvar, vaginal, and anal malignancies after a cervical cancer diagnosis.

Methods: This is a retrospective study examining data from the Surveillance, Epidemiology, and End Result Program between 1973 and 2013. Cumulative incidences of vulvar, vaginal, and anal cancers after the diagnosis of cervical cancer were assessed (n = 79,050). Read More

View Article
September 2018
2 Reads

The stimulation of the vaginal immune system with short-term administration of a vaginal gel containing fraction of Propionibacterium acnes, hyaluronic acid and polycarbophil is efficacious in vaginal infections dependent on disorders in the vaginal ecosystem.

Gynecol Endocrinol 2018 Oct 12;34(10):880-883. Epub 2018 Apr 12.

a Department of Surgical Sciences , University of Cagliari , Cagliari , CA , Italy.

The vaginal immune system (VIS) is the first defense against antigens recognized as foreign. Substances capable of locally activating the VIS could be a valid strategy to treat vulvo-vaginal infections (VVI), caused by changes in the vaginal ecosystem, such as bacterial vaginosis (BV), vulvo-vaginal candidiasis (CA), and mixed vaginitis (MV). Bacterial lysates, obtained by crushing bacterial cultures, exert immuno-modulatory activities. Read More

View Article
October 2018
8 Reads

Lymphedema following gynecological cancer: Results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors.

Gynecol Oncol 2017 09 16;146(3):623-629. Epub 2017 Jun 16.

The University of Queensland, Brisbane, Queensland, Australia; Royal Brisbane and Women's Hospital, Queensland Centre of Gynaecological Research, Brisbane, Queensland, Australia.

Objective: Cancer-related lymphedema is a debilitating condition that adversely influences function, health and quality of life. The purpose of this study was to assess the prevalence, incidence, and risk factors of lower-limb lymphedema pre- through to 24months post-surgery for gynecological cancer.

Methods: A clinic-based sample of women (n=408) with gynecological cancer participated in a prospective, longitudinal study (2008-2011) using self-reported measures (swelling in one or both legs) and objectively measured lymphedema (bioimpedance spectroscopy) at baseline (pre-surgery), six weeks-three months, 6-12months, and 15-24months post-surgery. Read More

View Article
September 2017
7 Reads

Relationship between changes in vulvar-vaginal atrophy and changes in sexual functioning.

Maturitas 2017 Jun 22;100:57-63. Epub 2017 Mar 22.

Pfizer Ltd, Tadworth, Surrey, UK. Electronic address:

Objective: Conjugated estrogens/bazedoxifene (CE/BZA) has demonstrated benefit in vulvar-vaginal atrophy (VVA, part of genitourinary syndrome of menopause) and the sexual function domain of the Menopause-specific Quality of Life (MENQOL) questionnaire. The study's objective was to determine the relationship of VVA symptoms and clinical parameters with MENQOL sexual functioning in postmenopausal women receiving VVA treatment.

Study Design: Post hoc analysis data were derived from the 12-week SMART-3 trial, which evaluated CE/BZA's effect on VVA in nonhysterectomized postmenopausal women (aged 40-65 years) experiencing one or more moderate to severe VVA symptoms (dryness, itching/irritation, pain with intercourse) and vaginal pH>5. Read More

View Article
June 2017
30 Reads

The association of pre-treatment HPV subtypes with recurrence of VIN.

Eur J Obstet Gynecol Reprod Biol 2017 Apr 1;211:37-41. Epub 2017 Feb 1.

Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy.

Objective: To assess whether pre-treatment HPV types are associated with recurrence of high-grade vulvar intraepithelial neoplasia (VIN2+).

Study Design: Data of consecutive patients with pretreatment HPV DNA test undergoing treatment for VIN2+ were retrospectively collected. Risk factors promoting the risk of VIN2+ persistence and recurrence were analyzed using Kaplan-Meier and Cox hazard proportional models. Read More

View Article
April 2017
11 Reads

Paget's disease of the vulva: A review of 89 cases.

Gynecol Oncol Rep 2017 Feb 30;19:46-49. Epub 2016 Dec 30.

Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

The purpose of this study was to retrospectively review the clinical characteristics and outcomes of a series of women with Paget's disease of the vulva. A retrospective review was performed of 89 women with Paget's disease of the vulva evaluated at a single institution between 1966 and 2010. Medical records were reviewed for demographic information, clinical data, pathologic findings, treatment modalities and outcomes. Read More

View Article
February 2017
16 Reads

New options for menopausal symptoms after 15 years of WHI Study.

Minerva Ginecol 2017 Apr 14;69(2):160-170. Epub 2016 Dec 14.

Department of Obstetrics and Gynecology, San Carlos Clinic Hospital, Madrid, Spain.

Menopausal symptoms include vasomotor symptoms (VMS), vulvar-vaginal atrophy, and loss of bone mass associated with an increased risk of fracture. Treatment of VMS consists of lifestyle changes, hormone treatment (estrogens with and without progestogens, tissue selective estrogens complex or conjugated estrogens and bazedoxifene [CE/BZA], progestogens, and tibolone), and nonhormonal treatments. Genitourinary symptoms due to vulvar-vaginal atrophy are treated with systemic and local hormones, moisturizer creams and gels, CE/BZA, and a selective estrogen receptor modulator (ospemifene). Read More

View Article
April 2017
10 Reads

A Giant Vulvar Mass: A Case Study of Cellular Angiofibroma.

Case Rep Obstet Gynecol 2016 16;2016:2094818. Epub 2016 May 16.

Obstetrics and Gynecology Clinic, Kocaeli Derince Education and Research Hospital, 41900 Kocaeli, Turkey.

Cellular angiofibroma is a mesenchymal tumor that affects both genders. Nucci et al. first described it in 1997. Read More

View Article
June 2016
9 Reads

Targeted Treatment of a Rare Vaginal Sarcoma With an Anaplastic Lymphoma Kinase Inhibitor.

Obstet Gynecol 2016 Feb;127(2):222-5

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California-Irvine Medical Center, Orange, and Kaiser Permanente, Southern California, Irvine, California.

Background: Anaplastic lymphoma kinase is a tyrosine kinase receptor that can become oncogenic. Crizotinib is a tyrosine kinase inhibitor that shows activity in patients with anaplastic lymphoma kinase rearrangements that have failed conventional therapies.

Case: A 34-year-old woman presented with a painful 3-cm left vulvar-vaginal mass, which was excised and determined to be a sarcoma with positive surgical margins. Read More

View Article
February 2016
1 Read

Evaluation of efficacy and safety of conjugated estrogens/bazedoxifene in a Latin American population.

Climacteric 2016 Jun 3;19(3):261-7. Epub 2016 Mar 3.

c Pfizer Inc, Collegeville , PA , USA.

Introduction Conjugated estrogens/bazedoxifene (CE/BZA) relieves menopausal symptoms and increases bone mineral density (BMD). Objective To evaluate CE/BZA in a Latin American subpopulation from randomized, double-blind, phase-3, multinational trials. Methods Safety data were pooled from three trials from non-hysterectomized postmenopausal Latin American women assigned to CE 0. Read More

View Article
June 2016
7 Reads

Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.

Clin Cancer Res 2016 05 26;22(10):2342-50. Epub 2016 Jan 26.

Department of Clinical Oncology, Leiden University Medical Centre, Leiden, the Netherlands.

Purpose: Therapeutic vaccination with human papillomavirus type 16 (HPV16) E6 and E7 synthetic long peptides (SLP) is effective against HPV16-induced high-grade vulvar and vaginal intraepithelial neoplasia (VIN/VaIN). However, clinical nonresponders displayed weak CD8(+) T-cell reactivity. Here, we studied if imiquimod applied at the vaccine site could improve CD8(+) T-cell reactivity, clinical efficacy, and safety of HPV16-SLP (ISA101). Read More

View Article
May 2016
37 Reads

The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer.

Gynecol Oncol 2016 Mar 11;140(3):420-4. Epub 2016 Jan 11.

Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Av, room C278, New York, NY 10065, USA.

Objectives: To evaluate the changes in prognostic impression and patient management following PET/CT in patients with vulvar and vaginal carcinoma; and to compare PET/CT findings with those of conventional imaging modalities.

Methods: We summarized prospectively and retrospectively collected data for 50 consecutive patients from our institution that enrolled in the National Oncologic PET Registry and underwent FDG-PET/CT for a suspected or known primary or recurrent vulvar/vaginal cancer.

Results: 54/83 (65%) studies included had a diagnosis of vulvar cancer, and the remaining 29/83 (35%), a diagnosis of vaginal cancer. Read More

View Article
March 2016
1 Read

Primary genitourinary melanoma: Epidemiology and disease-specific survival in a large population-based cohort.

Urol Oncol 2016 Apr 28;34(4):166.e7-14. Epub 2015 Dec 28.

Department of Urology, Massachusetts General Hospital, Boston, MA. Electronic address:

Background: Primary genitourinary (GU) melanoma is a rare disease, which is poorly characterized.

Objective: To examine clinical characteristics and survival outcomes of primary GU melanoma among men and women.

Design, Setting, And Participants: Retrospective study using the Surveillance, Epidemiology, and End Results database (1973-2010) was used to identify primary GU melanoma cases by tumor site and histology codes. Read More

View Article
April 2016
15 Reads

Dying well: How equal is end of life care among gynecologic oncology patients?

Gynecol Oncol 2016 Feb 17;140(2):295-300. Epub 2015 Dec 17.

The Department of Medical Education, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Objective: To identify disparities in utilization of end of life (EoL) resources by gynecologic oncology (GO) patients.

Methods: This retrospective analysis of the medical records of GO patients treated 1/2007-12/2011 and deceased 1/2012-8/2014 evaluated patient demographics, disease characteristics, and utilization of EoL resources. Chi-square, Fisher's exact test, Mann Whitney and Kruskal-Wallis tests were used for statistical analysis. Read More

View Article
February 2016
12 Reads

Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use.

Expert Opin Pharmacother 2015 3;16(17):2703-14. Epub 2015 Dec 3.

b Department of Obstetrics, Gynecology, and Reproductive Sciences , University of California San Francisco East Bay Physicians Medical Group affiliated with Sutter East Bay Medical Foundation , Berkeley , CA 94704 , USA.

Introduction: Vulvar vaginal atrophy (VVA), a component of genitourinary syndrome of menopause, is a chronic, progressive medical condition that results from estrogen deficiency at menopause. Ospemifene is a nonhormonal, estrogen receptor agonist/antagonist (ERAA) FDA-approved for the treatment of moderate to severe dyspareunia, a symptom of VVA, due to menopause.

Areas Covered: PubMed was searched from inception to March 2015 with keywords ospemifene and vulvar vaginal atrophy; no other similar clinical reviews were found. Read More

View Article
June 2016
1 Read

Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: The AGATA study.

Maturitas 2016 Jan 14;83:40-4. Epub 2015 Sep 14.

Obstetrics and Gynecology, University of Modena and Reggio Emilia, Italy. Electronic address:

Objectives: Prevalence of vulvar-vaginal atrophy (VVA) has been always investigated by phone or web interview without any objective evaluation. Objective signs associated with symptoms of VVA are now termed genitourinary syndrome of menopause (GSM). This multi-centric study was performed in order to provide nation-wide data on the prevalence and management of GSM. Read More

View Article
January 2016
8 Reads

Gynecologic cancer outcomes in the elderly poor: A population-based study.

Cancer 2015 Oct 31;121(20):3591-9. Epub 2015 Jul 31.

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

Background: Adults aged ≥65 years who are dually enrolled in Medicare and Medicaid are an at-risk group in health care. However, to the best of the authors' knowledge, the outcomes of women with gynecologic cancers in this population are unknown.

Methods: The current study was a population-based cohort study of North Carolina state cancer registry cases of uterine, ovarian, cervical, and vulvar/vaginal cancers (2003-2009), with linked enrollment in Medicare and state Medicaid. Read More

View Article
October 2015
20 Reads

Malignancies in systemic lupus erythematosus: a 2015 update.

Curr Opin Rheumatol 2015 Sep;27(5):454-60

aDepartment of Medicine, Cumming School of Medicine, Health Sciences Centre, Foothills Campus, University of Calgary, Calgary, Alberta bDepartment of Medicine and of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada cDivision of Rheumatology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA dDivision of Rheumatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Purpose Of Review: Patients with systemic lupus erythematosus (SLE) have altered incidences of certain malignancies as compared with the general population. This review summarizes the recent literature on risk of malignancy in SLE and proposed mechanisms for these altered susceptibilities.

Recent Findings: Recent studies have confirmed previous data showing an increased risk of non-Hodgkin's lymphoma, lung, liver, vulvar/vaginal, and thyroid malignancies, whereas demonstrating a decreased risk of breast and prostate cancer. Read More

View Article
September 2015
4 Reads

Global availability of data on HPV genotype-distribution in cervical, vulvar and vaginal disease and genotype-specific prevalence and incidence of HPV infection in females.

Infect Agent Cancer 2015 28;10:13. Epub 2015 Apr 28.

Merck Center for Observational and Real-World Evidence, West Point, PA USA.

Background: Country-level HPV genotyping data may be sought by decision-makers to gauge the genotype-specific burden of HPV-related diseases in their jurisdiction and assess the potential impact of HPV vaccines. We investigated, by country, the availability of published literature on HPV genotypes in cervical, vaginal and vulvar cancers and intraepithelial neoplasms (CINs, VaINs and VINs) and on prevalence and incidence of genital HPV infections among women without clinically manifest disease.

Findings: Primary sources of publications were the PubMed/Medline and EMBASE databases. Read More

View Article
May 2015
9 Reads

The impact of multimorbidity on quality of life among midlife women: findings from a U.S. nationally representative survey.

J Womens Health (Larchmt) 2015 May;24(5):374-83

1 Boston Health Economics, Inc. , Waltham, Massachusetts.

Background: Little is known about the prevalence and cumulative burden of coexisting health conditions including chronic joint and muscular pain, urinary incontinence (UI), depression, osteoporosis risk, moderate/severe vasomotor symptoms, and vulvar/vaginal atrophy (VVA). We surveyed a nationally representative U.S. Read More

View Article
May 2015
8 Reads
2 PubMed Central Citations(source)
1.900 Impact Factor

Obesity is associated with worse quality of life in women with gynecologic malignancies: an opportunity to improve patient-centered outcomes.

Cancer 2015 Feb 23;121(3):395-402. Epub 2014 Sep 23.

Division of Gynecologic Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Cancer Care Quality Training Program, Division of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

Background: The objective of the current study was to evaluate the effect of obesity on pretreatment quality of life (QoL) in gynecologic oncology patients.

Methods: The authors analyzed collected data from an institution-wide cohort study of women with gynecologic cancers enrolled from August 2012 to June 2013. The Functional Assessment of Cancer Therapy-General, site-specific symptom scales, and the National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) global mental and physical health tools were administered. Read More

View Article
February 2015
6 Reads

The first leg video endoscopic groin lymphadenectomy in vulvar cancer: A case report.

Int J Surg Case Rep 2014 4;5(8):455-8. Epub 2014 Jun 4.

Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy.

Introduction: The current management of vulvar cancer depends on the extension of disease, and includes primary tumor resection with safety margin as well as inguinofemoral lymph node staging. We report the case of the first leg videoendoscopic inguinal lymphadenectomy performed in a woman with a squamous cell vulvar carcinoma.

Presentation Of Case: A 74 years old female referred to our institution complaining of vulvar mass associated with bleeding and swelling from external genitals, vaginal burning sensation and dysuria for 5 months. Read More

View Article
August 2014
2 Reads

Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss.

Steroids 2014 Nov 11;90:71-81. Epub 2014 Jun 11.

Pfizer Inc, Collegeville, PA, United States.

Conjugated estrogens (CE) combined with the selective estrogen receptor modulator (SERM) bazedoxifene (BZA) is a new option for alleviating menopausal symptoms and preventing postmenopausal bone loss. The rationale for developing the tissue selective estrogen complex (TSEC) CE/BZA was to combine CE's benefits with the SERM's tissue-specific properties to offset estrogenic stimulation of endometrial and breast tissue. TSECs provide a progestin-free alternative to traditional estrogen-progestin therapy (EPT) in women with a uterus. Read More

View Article
November 2014
6 Reads

Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene.

Maturitas 2014 Jul 26;78(3):212-8. Epub 2014 Apr 26.

Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426, USA. Electronic address:

Objective: Describe the effects of conjugated estrogens/bazedoxifene (CE/BZA), a new treatment for vasomotor symptoms (VMS) and osteoporosis prevention, on menopause-specific quality of life (MSQOL) across different patient population types in phase 3 clinical trials.

Design: MSQOL was prospectively evaluated in 4 randomized, double-blind, placebo-controlled studies. The populations studied included healthy, non-hysterectomized postmenopausal women with symptomatic VMS or vulvar-vaginal atrophy (VVA) and general postmenopausal women (eligible regardless of symptoms). Read More

View Article
July 2014
17 Reads

Preoperative quality of life and surgical outcomes in gynecologic oncology patients: a new predictor of operative risk?

Gynecol Oncol 2014 Jun 12;133(3):546-51. Epub 2014 Apr 12.

Division of Gynecologic Oncology, University of North Carolina School of Medicine, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.

Objective: Quality of life (QoL) for women with gynecologic malignancies is predictive of chemotherapy related toxicity and overall survival but has not been studied in relation to surgical outcomes and hospital readmissions. Our goal was to evaluate the association between baseline, pre-operative QoL measures and 30-day post-operative morbidity and health resource utilization by gynecologic oncology patients.

Methods: We analyzed prospectively collected survey data from an institution-wide cohort study. Read More

View Article
June 2014
2 Reads

An overview of current and emerging SERMs.

J Steroid Biochem Mol Biol 2014 Sep 22;143:207-22. Epub 2014 Mar 22.

Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426, USA.

Selective estrogen receptor modulators (SERMs) are compounds that exhibit tissue-specific estrogen receptor (ER) agonist or antagonist activity, and are used for various indications, including treatment of breast cancer, osteoporosis, and menopausal symptoms. Endometrial safety has been a key differentiator between SERMs in clinical practice. For example, tamoxifen exhibits ER agonist activity in the uterus, resulting in an increased risk of endometrial hyperplasia and malignancy, whereas raloxifene and bazedoxifene have neutral effects on the uterus. Read More

View Article
September 2014
12 Reads

Botryomycosis of the vulva: a case report.

J Low Genit Tract Dis 2014 Jul;18(3):e80-3

Departments of 1Obstetrics and Gynecology and 2Dermatology and Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA.

Objective: Vulvar ulcers may be caused by various etiologies including infection, trauma, dermatosis, and cancer. We report a case of a vulvar ulcer caused by botryomycosis.

Case: An 85-year-old woman presented with vulvar itching, pain, bleeding, and ulcerations suspicious for cancer. Read More

View Article
July 2014
24 Reads

Advances in menopausal therapy: the tissue-selective estrogen complex.

Authors:
Anne Moore

J Am Assoc Nurse Pract 2013 Mar 26;25(3):126-33. Epub 2012 Nov 26.

Vanderbilt University School of Nursing, Nashville, Tennessee.

Purpose: Most menopausal women experience vasomotor symptoms, vulvar-vaginal atrophy, and/or bone loss. Although available estrogen and progestin therapies are effective in treating menopausal symptoms and preventing bone loss, some women may seek a therapy that provides symptom relief and has an improved tolerability profile. One option is a tissue-selective estrogen complex (TSEC), or the pairing of estrogen(s) with a selective estrogen receptor modulator (SERM) to achieve the benefits of each component with fewer side effects. Read More

View Article
March 2013
2 Reads

Outcomes in patients with mucosal melanomas.

J Surg Oncol 2013 Dec 16;108(8):516-20. Epub 2013 Oct 16.

Department of Surgery, Temple University School of Medicine, Philadelphia, Pennsylvania.

Background And Objective: Our goal was to evaluate the different subtypes of mucosal melanoma and describe specific variables that predict outcomes.

Methods: Prospective review of two tertiary care center databases identified 76 mucosal melanoma patients; 73 with complete records were included. Demographic and clinical data were analyzed. Read More

View Article
December 2013
2 Reads
5 PubMed Central Citations(source)
3.240 Impact Factor

Incidence of genitourinary conditions in women with a diagnosis of vulvar/vaginal atrophy.

Curr Med Res Opin 2014 Jan 18;30(1):143-8. Epub 2013 Oct 18.

EndoRheum Consultants LLC , Media, PA , USA.

Objectives: Vulvar/vaginal atrophy (VVA) is one genitourinary condition associated with a decline in estrogen. This may be bothersome for women following menopause. Although the clinical features of VVA and other conditions after menopause have been documented, few studies have quantified the magnitude of association between VVA and other genitourinary conditions. Read More

View Article
January 2014
8 Reads

Tissue-selective estrogen complexes for postmenopausal women.

Maturitas 2013 Nov 11;76(3):213-20. Epub 2013 Jul 11.

Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426, USA. Electronic address:

Although hormone therapy using estrogens plus progestogens (EPT) is effective for the management of menopausal symptoms (e.g., vasomotor symptoms and vulvar/vaginal atrophy) and prevention/treatment of postmenopausal osteoporosis, EPT is associated with safety and tolerability concerns. Read More

View Article
November 2013
10 Reads

Vulvar/vaginal melanoma: an updated surveillance epidemiology and end results database review, comparison with cutaneous melanoma and significance of racial disparities.

Int J Gynecol Cancer 2013 Jul;23(6):1118-25

Department of Obstetrics and Gynecology, Wayne State University and Karmanos Cancer Institute, Detroit, MI 48201, USA

Objective: We aimed to compare the differences in demographic features, clinicopathologic features, and survival in patients with vulvar/vaginal melanoma versus cutaneous melanoma with a special emphasis on race.

Materials And Methods: Data were obtained from the Surveillance Epidemiology and End Results database from 1973 to 2008. Kaplan-Meier curves and Cox multivariate model were used for statistical analysis. Read More

View Article
July 2013
4 Reads

Cytology of vulvar/vaginal paget disease: report of a case and review of the literature.

J Low Genit Tract Dis 2013 Oct;17(4):e26-30

University of Florida, Gainesville, FL.

Objective: We describe a woman with a long-standing history of Paget disease involving the vulva and vagina, who was previously diagnosed with a high-grade squamous lesion, atypical glandular cells, and adenocarcinoma on various different yearly Pap tests.

Materials And Methods: This article is a case report of this patient and a review of the literature concerning the cytology of Paget disease.

Results: By reviewing Pap test cytology findings, Paget cells were identified as atypical cell groups with enlarged nuclei and occasional prominent nucleoli and further characterized by immunoreactivity to carcinoembryonic antigen and gross cystic disease fluid protein that distinguished them from high-grade squamous lesion. Read More

View Article
October 2013
6 Reads

Outpatient end of life discussions shorten hospital admissions in gynecologic oncology patients.

Gynecol Oncol 2013 Jul 29;130(1):152-5. Epub 2013 Mar 29.

Division of Gynecologic Oncology, University of North Carolina, Chapel Hill, NC, United States.

Objective: The study goal was to determine whether prior outpatient exposure to hospice discussion altered the inpatient course and end-of-life (EOL) care among patients ultimately discharged to hospice.

Methods: Medical records from January 2009 to June 2012 were reviewed and data were abstracted under an IRB-approved protocol. Hospice discussions were identified in the last outpatient clinical encounter prior to admission. Read More

View Article
July 2013
4 Reads

Subpubic cartilaginous cyst presenting as acute urinary retention: a report and review of the literature.

Female Pelvic Med Reconstr Surg 2013 Jan-Feb;19(1):58-60

Michigan State University College of Human Medicine, Grand Rapids, MI, USA.

Introduction: A subpubic cartilaginous cyst is a rare and therefore poorly understood pathologic process involving the symphysis pubis. We describe a case of a postmenopausal female with acute urinary retention secondary to a periurethral cyst, and provide a literature review of previously reported cases of women with presenting complaints of a vulvar mass or pain. The differential diagnoses of a subpubic cartilaginous cyst, as well as management options, are discussed. Read More

View Article
April 2013
6 Reads

A review of clinical trials of human papillomavirus prophylactic vaccines.

Vaccine 2012 Nov;30 Suppl 5:F123-38

Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

End of study analyses of the phase III trials of prophylactic human papillomavirus (HPV) virus-like particle (VLP) vaccines in young women are now largely completed. Two distinct vaccines were evaluated, Gardasil(®) (Merck & Co., Whitehouse Station, NJ USA) a quadrivalent vaccine containing VLPs of types 6, 11, 16 and 18 and Cervarix(®) (GlaxoSmithKline Biologicals, Rixensart, Belgium), a bivalent vaccine containing VLPs of types 16 and 18. Read More

View Article
November 2012
2 Reads

Investigating a cluster of vulvar cancer in young women: a cross-sectional study of genital human papillomavirus prevalence.

BMC Infect Dis 2012 Oct 5;12:243. Epub 2012 Oct 5.

Discipline of Obstetrics & Gynaecology, The University of Adelaide, Adelaide, SA 5005, Australia.

Background: Vulvar cancer is a relatively rare malignancy, which occurs most often in postmenopausal women. We have previously identified a geographic cluster of vulvar cancer in young Indigenous women living in remote communities in the Arnhem Land region of Australia. In this population, we investigated the prevalence of oncogenic human papillomavirus (HPV) infection in anogenital samples (vulvar/vaginal/perianal area and cervix) and compared the overall, type-specific and multiple infection prevalence between sites. Read More

View Article
October 2012
4 Reads

Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women.

Climacteric 2013 Jun 5;16(3):338-46. Epub 2012 Oct 5.

Pfizer Inc, Collegeville, PA, USA.

Objectives: Bazedoxifene/conjugated estrogens (BZA/CE) has demonstrated efficacy in improving vasomotor and vulvar/vaginal atrophy symptoms in postmenopausal women. This study evaluated the endometrial safety of BZA/CE and effects on bone mineral density (BMD) compared with CE/medroxyprogesterone acetate (MPA) and placebo.

Methods: The Selective estrogens, Menopause, And Response to Therapy (SMART)-4 trial was a 1-year, multicenter, double-blind, randomized, placebo- and active-controlled, phase-3 study in non-hysterectomized, postmenopausal women (n = 1061; aged 40 -< 65 years). Read More

View Article
June 2013
18 Reads

Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.

Climacteric 2012 Oct 1;15(5):411-8. Epub 2012 Aug 1.

Department of Obstetrics and Gynecology, Division of Midlife Health, University of Virginia Health System, Charlottesville, VA 22908, USA.

Postmenopausal women with vasomotor and vaginal symptoms are commonly treated with estrogens or combined estrogen/progestin therapy (hormone therapy). However, hormone therapy is associated with some safety and tolerability concerns and its benefit/risk profile may vary for women based on their time since menopause. The tissue selective estrogen complex (TSEC) pairs a selective estrogen receptor modulator with one or more estrogens, with the goal of relieving menopausal symptoms and preserving bone mineral density without stimulating the breast or endometrium. Read More

View Article
October 2012
7 Reads

The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms.

Authors:
Risa Kagan

J Womens Health (Larchmt) 2012 Sep 3;21(9):975-81. Epub 2012 Jul 3.

Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California-San Francisco, CA, USA.

Background: Menopause-related health issues, including vasomotor symptoms, vulvar/vaginal atrophy, and osteoporosis, can decrease women's quality of life. Hormone therapy is the primary treatment option targeting both menopausal symptoms and bone loss but has been associated with some safety concerns. The tissue selective estrogen complex (TSEC) is a novel therapy, partnering a selective estrogen receptor modulator (SERM) with one or more estrogens. Read More

View Article
September 2012
3 Reads

Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy.

Int J Womens Health 2012 28;4:129-40. Epub 2012 Mar 28.

Pfizer Inc, Collegeville, PA, USA.

Many women experience bothersome vasomotor and vaginal symptoms during the menopausal transition. Decreasing levels of estrogens during menopause are also associated with reduced bone density and an increased risk of osteoporosis. Combined estrogen/progestin therapy (hormone therapy) effectively treats menopausal symptoms and prevents bone loss, but has been associated with some safety and tolerability concerns. Read More

View Article
October 2012
3 Reads

Using bazedoxifene plus conjugated estrogens for treating postmenopausal women: a comprehensive review.

Menopause 2012 Apr;19(4):479-85

Division of Reproductive Endocrinology and Infertility, Yale School of Medicine, New Haven, CT 06520, USA.

The objective of this article was to review clinical outcomes reported with the tissue selective estrogen complex containing bazedoxifene (BZA) and conjugated estrogens (CE) in postmenopausal women. PubMed was searched from inception to June 2011 using the key words bazedoxifene and conjugated estrogens. We reviewed six published articles reporting the clinical efficacy and safety outcomes of three different level I evidence, multicenter, blind, randomized, placebo-controlled studies. Read More

View Article
April 2012
3 Reads

The tissue selective estrogen complex: a promising new menopausal therapy.

Pharmaceuticals (Basel) 2012 Sep 4;5(9):899-924. Epub 2012 Sep 4.

Women's Health, Pfizer Inc., 500 Arcola Rd., Collegeville, PA 19426, USA.

Menopause is associated with health concerns including vasomotor symptoms, vulvar/vaginal atrophy (VVA), and osteoporosis. Estrogen therapy or combined estrogen-progestin therapy (EPT) are primary treatment options for menopausal symptom relief and osteoporosis prevention. Because EPT has been associated with some safety/tolerability concerns relating to undesirable effects of estrogen and progestin, alternative options are needed. Read More

View Article
September 2012
4 Reads

Pain and symptom assessment during multiple fractions of gynecologic high-dose-rate brachytherapy.

Brachytherapy 2011 Sep-Oct;10(5):352-6. Epub 2011 Jun 2.

Department of Radiation Oncology, London Regional Cancer Program, London, Ontario, Canada.

Purpose: A prospective assessment of tolerability of gynecologic brachytherapy was completed to determine adequacy of analgesia and symptom control for patients undergoing CT-guided brachytherapy, with multiple fractions delivered during a single applicator insertion.

Methods And Materials: Seventeen patients receiving high-dose-rate brachytherapy for gynecologic cancer (other than vaginal vault) completed ratings of pain intensity, anxiety, and nausea at five key time points before, during, and after brachytherapy. Symptoms were assessed with patient-reported scores using an 11-point numeric rating scale. Read More

View Article
January 2012
1 Read

Treating menopausal symptoms with a tissue-selective estrogen complex.

Authors:
Jeffrey P Levine

Gend Med 2011 Apr;8(2):57-68

Department of Family Medicine & Community Health and Obstetrics, Gynecology, & Reproductive Sciences, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903-0019, USA.

Vasomotor symptoms and vulvar-vaginal atrophy are common consequences of menopause, and the only treatment approved by the US Food and Drug Administration is hormone therapy. Because both physicians and women are concerned with the tolerability and safety profile of estrogen and estrogen plus progestin treatments, alternative menopause therapies are needed. An ideal menopause treatment modality would relieve menopausal vasomotor and vulvar-vaginal symptoms, maintain bone mass, and have neutral or beneficial cardiovascular effects, without stimulating the breast or endometrium. Read More

View Article
April 2011
4 Reads

Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE).

Authors:
R Lindsay

Osteoporos Int 2011 Feb 11;22(2):447-51. Epub 2010 Nov 11.

Clinical Research Center, Helen Hayes Hospital, Route 9W, West Haverstraw, NY 10993, USA.

Hormone therapy classically consists of an estrogen with an added progestin; however, concerns have been raised about the potential negative effects of progestin. The recent realization that estrogen agonist-antagonists or selective estrogen receptor modulators might be paired with estrogens instead of a progestin has led to the development of a novel form of menopausal therapy called tissue selective estrogen complex (TSEC). A TSEC is the pairing of a selective estrogen receptor modulator (SERM) with estrogen(s). Read More

View Article
February 2011
1 Read

Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex.

Menopause Int 2010 Sep;16(3):121-8

Obstetrics and Gynecology, Columbia University Medical Center, New York, NY, USA.

Menopause has been associated with vasomotor symptoms, vulvar-vaginal atrophy and osteoporosis. One of the goals in exploring the potential of selective estrogen receptor modulators (SERMs) was to determine if they could prevent fractures, reduce menopausal symptoms and treat vaginal atrophy, while being neutral or protective on the uterus, breast and cardiovascular system. However, no SERM to date has achieved this goal. Read More

View Article
September 2010
2 Reads

Burden of human papillomavirus infection and related comorbidities in men: implications for research, disease prevention and health promotion among Hispanic men.

P R Health Sci J 2010 Sep;29(3):232-40

Center for Evaluation and Sociomedical Research, Graduate School of Public Health, Medical Sciences Campus, University of Puerto Rico.

Genital human papillomavirus (HPV) infection is one of the most commonly diagnosed sexually transmitted infections world-wide. Over the last two decades, research has established a strong causal link between specific types of HPV infection and cancer, particularly cervical, anal, vulvar/vaginal, penile, and oropharyngeal cancer. Limited epidemiological studies of anogenital HPV infection have been conducted in Hispanic populations (including Puerto Rico), and population-based incidence and prevalence estimates of HPV infection among Hispanics are limited. Read More

View Article
September 2010
6 Reads